drugset / Trial / NCT06422650

Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia

NCT06422650

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of Nigella Sativa in 84 Hyperlipidaemic patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either Nigella Sativa 500 mg capsule daily or placebo capsule identical to Nigella Sativa twice daily for 8 weeks. Evaluation of lipid profile, SGPT, S.Creatinine will be before and after 8 weeks of intervention. Nigella Sativa related adverse events will be identified. Study outcome will establish safety and efficacy of Nigella Sativa in atorvastatin treated hyperlipidaemic patients

Timeline

Start
2023-08-24
Primary completion
2024-08-31
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nigella sativa Traditional medicine (herbal / TCM) 500 mg

Indications